Antofloxacin hydrochloride was approved by China Food and Drug Administration (CFDA) on Apr 15, 2009. It was developed and marketed as 优朋® by Anhui Globe in China.
Levornidazole hydrochloride is a fluoroquinolone antibacterial that mediated through the inhibition of bacterial DNA gyrase (bacterial topoisomerase II) activity. It inhibits bacterial DNA replication. It is used to treat acute exacerbation of chronic bronchitis (AECB), acute pyelonephritis (AP), acute cystitis and multiple folliculitis caused by bacteria.
优朋® is available as tablet for oral use, containing 0.1 g of free Antofloxacin. The recommended initial dose is 0.4 g orally once daily for adults and then 0.2 g once daily for 7-14 days.
Update Date:2016-03-14
Update Date:2015-07-29
Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
---|---|---|---|---|---|---|---|
2009-04-15 | Marketing approval | 优朋 | Acute exacerbation of chronic bronchitis (AECB),Acute cystitis,Acute pyelonephritis (AP) | Tablet | Eq. 0.1g Antofloxacin | Anhui Globe | 1.1类 |
Update Date:2015-08-27
Update Date:2015-11-17
Update Date:2015-09-29
1. EP0284935A1 / CN88101741A.